BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
🇺🇸United States
Effects of Low-Dose Doxycycline on Oral Bone Loss
Phase 3
Completed
- Conditions
- Periodontitis
- Interventions
- Drug: 20 mg doxycycline hyclateDrug: Placebo
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 128
- Registration Number
- NCT00066027
- Locations
- 🇺🇸
University of Nebraska Medical Center, College of Dentistry, Lincoln, Nebraska, United States
🇺🇸Department of Oral Biology and Pathology, Stony Brook, New York, United States
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- University of Nebraska
- Registration Number
- NCT00007865
- Locations
- 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
Phase 2
Terminated
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 19
- Registration Number
- NCT00006478
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
Phase 1
Completed
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 26
- Registration Number
- NCT00031642
- Locations
- 🇺🇸
Eppley Cancer Center at University of Nebraska Medical Center, Omaha, Nebraska, United States
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- Interventions
- Procedure: peripheral blood stem cell transplantationRadiation: tositumomab and iodine I 131 tositumomab
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 50
- Registration Number
- NCT00006695
- Locations
- 🇺🇸
UNMC Eppley Cancer Center at University of Nebraska Medical Center, Omaha, Nebraska, United States